Nachweis von Antikörpern gegen SARS-CoV-2

Zusammenfassung

Der folgende Beitrag gibt einen Überblick über kommerziell erhältliche Testsysteme zur Untersuchung von Probenmaterial aus Blut auf verschiedene Antikörper gegen SARS-CoV-2. Dabei wird auch auf mögliche Anwendungen solcher Testungen eingegangen, angefangen von Seroprävalenz- und Longitudinalstudien über das Screening potenzieller Rekonvaleszenzplasmaspender bis hin zum Monitoring der humoralen Immunantwort nach Impfung gegen SARS-CoV-2.

Abstract

The following article provides an overview of commercially available test systems for screening blood samples for various antibodies against SARS-CoV-2. It also discusses possible applications of such testing, ranging from seroprevalence and longitudinal studies to screening of potential convalescent plasma donors and monitoring of the humoral immune response after vaccination against SARS-CoV-2.

Schlüsselwörter

SARS-CoV-2 - COVID-19 - Antikörper - Neutralisationstest - Rezeptorbindungsdomäne

Key words

SARS-CoV-2 - COVID-19 - antibody - neutralization test - receptor binding domain

• Literatur

• 1 Verity R, Okell LC, Dorigatti I. et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020; 20: 669-677
• 2 Aziz NA, Corman VM, Echterhoff AKC. et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nat Commun 2021; 12: 2117
• 3 Stringhini S, Wisniak A, Piumatti G. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet 2020;
• 4 Long QX, Liu BZ, Deng HJ. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;
• 5 Long QX, Tang XJ, Shi QL. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26: 1200-1204
• 6 Körper S, Jahrsdörfer B, Corman VM. et al. Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies. Transfus Med Hemother 2021; 48: 137-146
• 7 Herzog P, Drosten C, Muller MA. Plaque assay for human coronavirus NL63 using human colon carcinoma cells. Virol J 2008; 5: 138
• 8 Drosten C, Meyer B, Muller MA. et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med 2014; 371: 828-835
• 9 Jahrsdörfer B, Kroschel J, Ludwig C. et al. Independent side-by-side validation and comparison of four serological platforms for SARS-CoV-2 antibody testing. J Infect Dis 2021; 223: 796-801
• 10 Bryan A, Pepper G, Wener MH. et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol 2020; 58: e00941-20
• 11 Hoffmann M, Arora P, Groß R. et al. SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination. bioRxiv 2021;
• 12 Jahrsdörfer B, Groß R, Seidel A. et al. Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors. J Immunol 2021; 206: 2614-2622
• 13 Tan CW, Chia WN, Qin X. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol 2020; 38: 1073-1078
• 14 Li MY, Li L, Zhang Y. et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 2020; 9: 45
• 15 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;
• 16 Garcia-Beltran WF, Lam EC, St Denis K. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 2021; 184: 2372-2383.e9